Skip to main content
. 2022 Jul 19;36(12):9169–9178. doi: 10.1007/s00464-022-09400-w

Table 4.

Patients’ outcome

Characteristic Patients, No. (%) P value
Total
(n = 156)
Period 1
(n = 79)
Period 2
(n = 77)
MTL30 78 (50.0) 48 (60.8) 30 (39.0) .006*
In-hospital mortality 10 (6.4) 7 (8.9) 3 (3.9) .17
Efficacy of EVT
 Improvement of leakage 140 (89.7) 68 (86.1) 72 (93.5) .10
 Resolution of leakage 133 (85.3) 63 (79.7) 70 (90.9) .049*
 Resolution without additional procedures during or after EVT 94 (60.3) 40 (50.6) 54 (70.1) .013*
 Failure-to-cure† 18 (11.5) 12 (15.2) 6 (7.8) .12
Clavien–Dindo ≥ grade IIIb 74 (47.4) 42 (53.2) 32 (41.6) .09
CCI, mean (95%CI) 50.6 (46.8–54.3) 54.6 (49.3–59.9) 46.5 (41.3–51.8) .034*
Length-of-stay, median (quartiles), d 30 (20—53) 38 (23–60) 25 (16–44) .006*
Oral nutrition on discharge 121 (77.6) 56 (70.9) 65 (84.4) .043*

Values are n (%) unless otherwise indicated

MTL30 in-hospital-mortality or length-of-stay > 30 days; CCI comprehensive complication index;

Conversion to surgical therapy due to deteriorating leakage during EVT or death

*P < .05